Q-omics provides the consensus-scored EI24P4 profile across patient tissues and cancer cell-line models. EI24P4 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, EI24P4 is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, EI24P4 RNA expression shows 5,989 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, PRAD, and STAD as cancer lineages where EI24P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EI24P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EI24P4 survival associations across molecular data types. EI24P4 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EI24P4 RNA expression–survival associations across cancer types. High EI24P4 expression shows unfavorable associations in UCS, MESO, KIRC, ESCA, LIHC and PAAD. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for EI24P4 RNA expression.
This table summarizes EI24P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for EI24P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EI24P4 shows higher tumor expression in PRAD. The PRAD box plot shows higher EI24P4 RNA expression in tumor versus normal tissue (log2 FC = +0.011, t-test p = .048).
This table shows molecular features associated with EI24P4 in patient tissues and cancer cell lines. In patient samples, EI24P4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
